INTRODUCTION {#sec1}
============

Treatment of multiple myeloma generally consists of chemo-immunotherapy and autologous stem cell transplantation, with the latter prolonging disease-free survival and overall survival. Nowadays, myeloma is a chronic condition, the relapses and salvage therapies of the disease result in cumulative immunosuppression and a higher risk of infection ([@ref8]). Infection is a significant cause of morbidity and mortality in patients with multiple myeloma ([@ref7], [@ref8]).

In recent years, the most important advances in the treatment of transplant recipients and patients with haematological neoplasm have been accompanied by an increase in the incidence of the common fungal diseases and the emergence of some less common ones. Although new techniques (e. g., galactomannan detection) and new antifungals have appeared, these opportunistic infections remain difficult to diagnose and lead to a high mortality.

Some types of fungi can cause rare infections. One of them is *Saprochaete capitata* (formerly known as *Geotrichum capitatum* and *Blastoschizomyces capitatus*). It is a non-fermentative, non-encapsulated, urease-negative ascomycetous yeast ([@ref2], [@ref3]). It is a ubiquitous fungus ([@ref2]). *S. capitata* is part of the normal microbiota of the human skin and is frequently isolated from sputum and the digestive tract of healthy people ([@ref1]). Invasive human infection is rare.

Mostly, amphotericin and flucytosine are used for antifungal treatment, but experience is limited ([@ref3]--[@ref6]). Less data is available on voriconazole, but in vitro susceptibility is promising ([@ref3], [@ref4]).

We encountered a complete gastropulmonary fistula resulting from an invasive fungal infection in a patient with myeloma. The patient was successfully cured after a couple of surgical interventions.

CASE HISTORY {#sec2}
============

A 46-year-old woman presented with a persistent dry cough and vague left pleuritic pain that had worsened over the preceding three weeks.

The patient had a history of multiple myeloma (MM) since 2011. In June 2011, when she was 41 years old, asymptomatic multiple myeloma (immunoglobulin (Ig) A lambda) was diagnosed. Her bone marrow showed 70% plasma cells with Ig lambda light chain restriction, IgA-26 g/l.

The patient's first-line therapy consisted of a weekly regimen of oral CTD (cyclophosphamide 300 mg/m^2^ weekly, dexamethasone 40 mg, and thalidomide 100 mg). After four cycles, she achieved a very good partial response. Then, at 24 November 2011, she underwent autologous stem cell transplantation with minimal complications. The patient remained in remission for two years after the transplantation and then relapsed in September 2013.

The patient's second-line therapy consisted of a weekly regimen of oral cyclophosphamide (300 mg/m^2^), subcutaneous bortezomib (1.3 mg/m^2^), and oral dexamethasone 40 mg (CyBorD; also known as VCD). After four cycles, the patient achieved a very good second partial remission. The second autologous HSCT was performed on 9 January 2014 for consolidation. The patient remained in remission for 9 months after the transplantation and then relapsed MM in November 2014. Her blood data showed increased Ig A (g/L) -- 48.44, B2 microglobulin (mg/L) -- 8.82, total protein (g/l) -- 113.9, M gradient (%) -- 39.8, anaemia HGB (g/l) -- 84. The third-line therapy -- VTD-PACE regimen (bortezomib, thalidomide, dexamethasone, platinum, adriamycin, cyclophosphamide, and etoposide). After three cycles, the patient achieved a very good third partial remission. Then, the third autologous HSCT was performed.

Due to relapses, she received three lines of chemotherapy during four years of disease, each time receiving induction chemotherapy and high-dose chemotherapy with autologous peripheral blood stem cell transplantation (ASCT) for consolidation. After the last ASCT, which was performed on 11 March 2015, the patient had prolonged neutropenia and neutropenic fever.

On admission, her chest radiograph revealed subtle patchy consolidation in the left lower lobe and collection of fluid in the left pleural cavity ([Fig. 1](#fig1){ref-type="fig"}). She was treated with antibiotics (meronem and linesolid). Due to a probable fungal infection of the lungs, antifungal agents were administered (amphotericin B (1 mg/kg/24 hours), micafungin (300 mg/24 hours), voriconazole (600 mg/24 hours)). However, her general condition deteriorated and localized left pyopneumothorax was diagnosed ([Figs. 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}). Further work-up included fiberoptic gastroscopy and a computed tomography scan of the chest ([Fig. 4](#fig4){ref-type="fig"}). The CT showed a partial necrosis of the gastric fundus and left diaphragm, and clear communication of the stomach lumen with left pleural cavity. Fiberoptic gastroscopy was performed at the operation theatre right before the incision. It revealed a localised necrotic area of the fundus of the stomach. The area was covered with necrotic debris which was moving in conjunction with artificial ventilation. It was decided that the patient had a severe left-sided pleural empyema of fungal origin with bronchopleural and gastropleural fistulas at once. The Eloesser open-flap procedure with resection of VII--VIIIth subjacent posterolateral ribs was performed. Upon exploration, part of the lower lobe was found partially necrotized and was atypically resected using staplers. A huge ventriculopleural communication (about 5 cm in diameter) and a defect in the diaphragm were evaluated ([Fig. 5](#fig5){ref-type="fig"}). An open-window thoracostomy was created in order to facilitate treatment by daily packing of the cavity ([Fig. 6](#fig6){ref-type="fig"}). During open-window thoracostomy, the latissimus dorsi muscle was preserved with minimal injury to the anterior serratus muscle.

The invasive fungal disease of *Geotrichum capitatum* was confirmed from the operative specimen culture that was found to be resistant to fluconazole (MIC 48 μg/ml). Other antifungal agents as voriconazole (MIC 0.75 μg/ml), Amphotericin B (MIC 0.38 μg/ml), Anidulafungin (MIC 12 μg/ml), were reported with no interpretation. The susceptibility was assessed by the E-test procedure.

![Chest radiograph with a collection of fluid in the left pleural cavity (9 April 2015). A marked infiltration of the basal segments of the left lower lobe is presented](aml-23-169-g001){#fig1}

![Chest radiograph following one month after the initial investigation. Two air-fluid levels are clearly visible in the left side](aml-23-169-g002){#fig2}

![A lateral view](aml-23-169-g003){#fig3}

![Same-day CT scan of the chest. The contrast medium is clearly visible in the stomach. A short communication of the stomach lumen with the left pleural cavity through the diaphragmic defect was evaluated](aml-23-169-g004){#fig4}

Both amphotericin and voriconazole were used for antifungal treatment. Following surgery, the patient also received prolonged antifungal treatment with voriconazole.

![An intraoperative view. A large defect of the stomach fundus is clearly visible in the centre of the operative field](aml-23-169-g005){#fig5}

![A postoperative view after Eloesser open-flap formation. *Left*, a defect of the fundus is visible in the centre of eroded left diapfragm; *right*, the lower lobe of the left lung](aml-23-169-g006){#fig6}

Four weeks after the thoracostomy, thoracomyoplasty was performed to repair the gastropleural fistula. On laparotomy, the gastric fundus was freed from adjacent tissues and repaired. Intrathoracic transposition of the latissimus dorsi and anterior serratus muscle flaps was performed simultaneously to create a new diaphragm. The open-window thoracostomy was left open due to some small bronchial fistulas. The thoracostomy opening healed spontaneously during the following six months ([Fig. 7](#fig7){ref-type="fig"}, [8](#fig8){ref-type="fig"}).

![Chest radiograph taken seven months after the first operation (15 December 2015). Just a small area of parenchymal consolidation can be seen in the left lung](aml-23-169-g007){#fig7}

![A postoperative view of the chest wall seven months after the first surgical procedure](aml-23-169-g008){#fig8}

DISCUSSION {#sec3}
==========

Invasive pulmonary fungal infections (IFI) are frequently a lethal complication of hematologic malignancies and occur after both conventional chemotherapy and bone marrow transplantation (BMT), as well as in untreated severely neutropenic patients. The incidence of IFI is increasing ([@ref1]). The place of surgical interventions in such a group of patients is controversial. There are some publications concerning the value of pulmonary resection in hematologic patients who developed invasive pulmonary aspergillosis ([@ref9], [@ref12], [@ref13]). Bernard ([@ref13]) informed about 19 patients who were operated. Eight patients underwent emergency operations, before marrow recovery, to prevent massive hemoptysis. A lobectomy was performed in all cases. There was one postoperative death due to extensive aspergillosis. Seven patients were treated by elective resection of the residual mass. In the remaining four patients, surgical resection was performed as a diagnostic procedure. There were no postoperative deaths in this group of patients. The authors conclude that the combination of antifungal agents and surgical resection is an efficient strategy for the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancy. Chretien ([@ref9]) presents 50 haematological patients (22-year data) with IFI (invasive fungal infection) who underwent pulmonary resection. In 27 cases, it was an emergency procedure to avoid hemoptysis. At the time of surgery, 30% of patients were still neutropenic and 54% required platelet transfusion. Lobectomy or segmentectomy were performed in 80% and 20% of cases, respectively. Mortality at 30 and 90 days post-surgery was 6% and 10%, respectively. After surgery, median overall survival was 21 months.

Surgery is a feasible and valuable option in haematological patients with IFI, because it is associated with a low incidence of complications. In selected cases, lung resection should be performed in haematological patients with IFI in order to avoid possibly fatal complications.

CONCLUSIONS {#sec4}
===========

We report what is, to the best of our knowledge, the first case of invasive fungal infection (*Geotrichum capitatum*) successfully treated with intravenous amphotericin B, voriconazole and infected soft tissues (organs) surgery for the patient with multiple myeloma in prolonged neutropenia. The efficacy and safety of the surgery for infected soft tissues requires further evaluation.

Invasive fungal infection (IFI) is a recognized consequence of an immunocompromised state, but there are many possible underlying causes. These include neutropenia, exposure to high-dose corticosteroids, the presence of intravascular catheters, and prolonged exposure to broad-spectrum antibiotics.

Regardless, in our patient's case prolonged febrile neutropenia and the lung IFI persisted despite 20 days of intravenous micafungin. Pathological changes in the lungs remained despite treatment with intravenous micafungin.

We believe that in the case of our patient the systemic treatment alone was inadequate, and hypothesize that the use of the combination with surgery accounted for our patient's clinical improvement. In selected cases, lung resection should be performed in haematological patients with IFI in order to avoid possibly fatal complications.
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